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Abstract  
 
Background & Objective: The OMERACT Filter 2.0 framework was developed in 2014 to aid 
core outcome set development by describing the ĨƵůůƵŶŝǀĞƌƐĞŽĨ ‘ŵĞĂƐƵƌĂďůĞĂƐƉĞĐƚƐŽĨ
ŚĞĂůƚŚĐŽŶĚŝƚŝŽŶƐ ? from which core domains can be selected. This paper provides 
elaborations and updated concepts (OMERACT Filter 2.1).  
Methods: At OMERACT 2018, we discussed challenges in the framework application caused 
by unclear or ambiguous wording and terms, and incompletely developed concepts. 
Results:  The updated OMERACT Filter 2.1 framework makes  benefits and harms explicit, 
clarifies concepts, and improves naming of various terms. 
Conclusion: We expect that the Filter 2.1 framework will improve the process of core set 
development.  
 
Introduction 
Since 1992, The Outcome Measures in Rheumatology (OMERACT) initiative has successfully 
improved outcome measurement for many rheumatologic conditions by developing widely 
ĞŶĚŽƌƐĞĚ ‘ĐŽƌĞŽƵƚĐŽŵĞŵĞĂƐƵƌĞŵĞŶƚƐĞƚƐ ? that include a minimum set of outcome 
measures to be reported in all randomized controlled trials (RCTs) in a given health 
condition. As OMERACT grew, its framework and process to develop core domain sets and 
core outcome measurement sets needed clarification. This was provided by the OMERACT 
Filter 2.0 Framework and process published in 2014.(1) Briefly, to improve content validity of 
core sets, Filter 2.0 intended to describe  ƚŚĞĨƵůůƵŶŝǀĞƌƐĞŽĨ ‘ŵĞĂƐƵƌĂďůĞĂƐƉĞĐƚƐŽĨŚĞĂůƚŚ
ĐŽŶĚŝƚŝŽŶƐ ?by introducing four  ‘Core ƌĞĂƐ ?ŝŶǁŚŝĐŚĂůůĚŽŵĂŝŶƐŽĨŵĞĂƐƵƌĞŵĞŶƚǁŽƵůĚĨĂůů P
Death, Life Impact, Resource Use and Pathophysiological Manifestations (Figure 1). Core set 
developers were required to choose at least one domain in each area, except for the area of 
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resource use, which was considered optional. Since its launch Filter 2.0 has been successfully 
applied to the development of several core sets both within- and outside OMERACT (2-8). 
However, there are challenges in application caused by ambiguous wording and terms and 
incompletely specified concepts. In this paper, the OMERACT Executive proposes a further 
elaboration and update of the Framework. As such, it is not a product of consensus at the 
conference, but its utility will continue to be evaluated by the users, i.e. the OMERACT 
community.  
[INSERT FIGURE 1] 
Challenges in the original framework 
In the original framework (FŝŐƵƌĞ ? ? ?ĂĚǀĞƌƐĞĞǀĞŶƚƐĂŶĚĐŽŶƚĞǆƚ ‘ĚĂŶŐůĞĚ ?ƵŶĚĞƌŶĞĂƚŚƚŚĞ
areas and domains with examples. During the first development of the framework we 
realized that these concepts were essential, but struggled to identify the optimal way to 
include them. In addition, many users raised concerns with the core areas of Death (as being 
distinct from an adverse event) and Pathophysiological Manifestations. Death is particularly 
a problem for core sets in health conditions that do not necessarily impact survival; selection 
of domains for Pathophysiological Manifestations are a problem when the health condition 
is nonspecific or no clear pathophysiology has been recognized, e.g. fibromyalgia or non-
specific low back pain. Finally, proper placement of domains within the areas of Life Impact 
or Pathophysiological Manifestations can be difficult or arbitrary, with some domains 
appearing to fit into both due to lack of clear criteria for placement.  
Improving the terminology and ordering of the Core Areas 
To enable improvement, we must first return to the primary purpose of the framework. A 
core domain set specifies the domains that should always be measured in a trial of an 
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intervention targeted at a health condition, regardless of whether the primary study 
question includes these domains (1). The framework is designed to help the development of 
core sets that meet minimum requirements of content validity. Each core area in the 
framework has a specific role ?ĂŶĚƚŽŐĞƚŚĞƌƚŚĞǇĐŽŶƚĂŝŶƚŚĞǁŚŽůĞ ‘ƵŶŝǀĞƌƐĞ ?ŽĨdomains 
(concepts) that one could conceivably measure to assess the effects of an intervention. For 
each core set, OMERACT helps to ensure content validity by mandating the choice of at least 
one domain in each area (except for societal/resource use which is optional). We have 
reordered the areas to better align them with existing biopsychosocial and biomedical 
models (9, 10). The Framework intends to complement these models by its focus on the 
choice of domains to optimize breadth and content of a core set. A key clarification 
discussed in more detail below is that beneficial and harmful effects of interventions are 
measured in the same domain space: for example, methotrexate can increase participation 
through improvements in rheumatoid arthritis activity, but can also decrease participation 
due to severe intermittent nausea. (Figure 2)  
[INSERT FIGURE 2] 
 
 
Pathophysiology: Manifestations/Abnormalities 
A health condition manifests itself by abnormal physiology (pathophysiology) as symptoms, 
signs, biomarker signals, or events. These include for example fever, fatigue, oral ulcers, 
rash, range of motion limitation, anemia, hematuria, erosive damage, etc. All of these can be 
seen as manifestations of the underlying health condition (disease, morbidity) and can be 
distinguished from their impact (see below). A better term for the concept is 
Pathophysiology, and the core ĂƌĞĂƚĞƌŵĐĂŶďĞƐŚŽƌƚĞŶĞĚƚŽ ‘DĂŶŝĨĞƐƚĂƚŝŽŶƐ ? ?In the 
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International Classification of Function (ICF) Framework, such manifestations are captured 
ƵŶĚĞƌ ‘ďŽĚǇƐƚƌƵĐƚƵƌĞƐ ?ĂŶĚ ‘ďŽĚǇĨƵŶĐƚŝŽŶƐ ? (10). To fully assess an intervention, we think it 
is essential that its effects on the underlying pathophysiology are captured; hence this is a 
core area. In many conditions, the pathophysiology may not be fully elucidated, so the 
selection of domain(s) for this area must be Ă ‘ďĞƐƚĞĨĨŽƌƚ ?. Furthermore, the core domain set 
will need to be regularly updated to track developments in understanding. In some health 
conditions, pathophysiology is left undefined  ‘ďǇĚĞĨŝŶŝƚŝŽŶ ? (e.g. nonspecific low back pain)  
or it is heterogeneous (e.g.  ‘ƐŚŽƵůĚĞƌĚŝƐŽƌĚĞƌƐ ?). In such cases, the development group has 
two options: 1) they can decide to place domain(s) in this area chosen to reflect the main 
manifestation(s)  ?Ğ ?Ő ? ‘ƉĂŝŶ ? ?ƌĞŶĂůĨƵŶĐƚŝŽŶ ?); or 2) they leave the core set incomplete, to be 
further specified per trial. In the latter case, the core set can state that trialists have to 
choose a domain that aligns with the manifestations that are the target of intervention in 
that RCT. In both cases, the area of pathophysiological manifestations will measure at least 
one domain. 
 
Impact: Life Impact, Death/Lifespan and Societal/Resource Use 
The description of outcome as  ‘how a patieŶƚĨĞĞůƐ ?ĨƵŶĐƚŝŽŶƐŽƌƐƵƌǀŝǀĞƐ ? has been ascribed 
to Temple (11), and is frequently quoted in documents of the US Food and Drug 
Administration (12). It certainly concurs with FƌŝĞƐĞƚĂů ? ?ƐƐĞŵŝŶĂůǁŽƌŬŽŶƚŚĞ,ĞĂůƚŚ
Assessment Questionnaire:  ‘A patient certainly desires to be free of pain, functioning 
normally, experiencing minimal treatment toxicity, and financially solvent ? (13). In the 
Framework ?ƚŚŝƐŝƐĞŶƚŝƚůĞĚ “Impact ?ĂŶĚencompasses both the impact on the life lived 
(feeling and functioning), and on lifespan (survival, mortality). For patients, usually it is not, 
or not only the manifestation but its impact that is relevant and should be measured. Life 
 11 
impact is captured by concepts such as well-being, health perception, utility, and by the ICF 
categories of activities and participation. It also largely overlaps with the concept or global 
domain of  ‘ŚĞĂůƚŚ-ƌĞůĂƚĞĚƋƵĂůŝƚǇŽĨůŝĨĞ ?, and ability to live and function independently. 
Although such a global domain can be useful, OMERACT encourages developers to try and 
choose more specific domains that better align with the lived experience of the condition for 
which the core set is being developed. So for example, fatigue and sleep loss have a major 
impact on quality of life in RA, as does social isolation in psoriasis, and weight gain in 
osteoarthritis; if such impacts are deemed core, it may make more sense to propose these as 
core domains rather than to capture them under a generic  ‘quality of life ? domain. 
To date, a symptom or event has frequently been taken as a proxy for its impact, but this is 
usually suboptimal. For example, core set developers could consider the quality and 
intensity of pain as the manifestation, but choose not to include impact of pain as a separate 
domain (e.g.,  ‘ƉĂŝŶŝŶƚĞƌĨĞƌĞŶĐĞ ? ? ?WĂŝŶintensity would then be seen to represent both 
pathophysiology and life impact. Using events as proxy for impact is more problematic. For 
example  ‘ďŽŶĞĨƌĂĐƚƵƌĞ ? is a pathophysiologic manifestation, but its impact can be very small 
or very large, and span across many different concepts, e.g. inability to perform key activities 
of daily living that differ depending on the location of the fracture or the way it has healed. 
Choosing domains that directly address the impact(s) is preferable and recommended in this 
framework. 
Death/Lifespan as target of intervention is pertinent in potentially fatal health conditions 
such as vasculitis, systemic sclerosis, and lupus erythematosus. In most other rheumatologic  
conditions, in the context of a clinical trial death is only a rare adverse event; in core sets for 
ƐƵĐŚĐŽŶĚŝƚŝŽŶƐƚŚŝƐĐŽƌĞĂƌĞĂǁŝůůƐŝŵƉůǇďĞĨŝůůĞĚďǇƚŚĞĚŽŵĂŝŶ ‘ĐŽƵŶƚŽĨĚĞĂƚŚƐ ? (see also 
 12 
next section: benefit and harm). The term lifespan was added to capture the duration of 
living rather than only focusing on the discrete event of death. 
The impact of health conditions on individuals also translates to impact on society: these are 
expressed as health care utilization leading to so-ĐĂůůĞĚ ‘ĚŝƌĞĐƚ ?ĐŽƐƚƐ ?ĂŶĚ productivity losses 
leading to  ‘ŝŶĚŝƌĞĐƚ ?ĐŽƐƚƐ ?ůƚŚŽƵŐŚĐůĞĂƌůǇŝŵƉŽƌƚĂŶƚ ?ǁĞŵĂŝŶƚĂŝŶKDZd ?ƐŽƌŝŐŝŶĂů
choice to regard this area as optional, meaning that developers are not mandated to choose 
a domain from this area in their core set.  
Benefit and Harm: intended and unintended effects of intervention 
To study the effects of an intervention, our focus is on measuring changes (improvement or 
deterioration) or counting events (good or bad); however, apart from the intervention such 
changes can be due to the natural course of the disease/health condition, or to unrelated 
comorbidities. Only in a properly designed clinical trial can causal inferences be made with 
confidence, and only at the group level: randomization creates groups with similar 
prognostic characteristics, and differences above random error (in mean change or the 
occurrence of events) can then be ascribed to the interventions administered.(14) 
Interventions are targeted to reduce, eliminate, or prevent the manifestations of the health 
condition or their impact. When the intervention has beneficial effects, we say it is 
successful. However, interventions can also cause harm by inducing new manifestations or 
worsening existing ones. dŚĞŽƌŝŐŝŶĂůĨƌĂŵĞǁŽƌŬƉĂƉĞƌĂůƌĞĂĚǇƐƚĂƚĞĚ P ‘ĞŶĞĨŝƚĂŶĚŚĂƌŵ
ĐĂŶďĞƌĞŐĂƌĚĞĚĂƐŽƉƉŽƐŝƚĞĚŝƌĞĐƚŝŽŶƐŽŶŽŶĞ ‘ ‘ŝŵƉĂĐƚƐĐĂůĞ ? ? ?ŵĞĂƐƵƌĂďůĞŝŶŽŶĞŽĨƚŚĞĐŽƌĞ
ĂƌĞĂƐ ? ?dŚŝƐŝƐĨƵƌƚŚĞƌĐůĂƌŝĨŝĞĚŝŶƚhe current elaboration (Figure 2,3): the framework areas 
allow for domains that can measure benefit, harm, or both, resulting in a  ‘ŶĞƚĞĨĨĞĐƚ ?. For 
example, an intervention can increase work/family/leisure participation due to decreased 
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pain and stiffness (benefit), but at the same time decrease participation due to increased 
fatigue (harm). Or in the case of glucocorticoids and osteoporosis, these agents have 
negative effects on bone, but in rheumatoid arthritis they also counteract the negative 
effects of inflammation on bone. 
 
Example Domains 
[INSERT FIGURE 3] 
In Figure 3, the concepts of benefit and harm are again distinguished and example domains 
are included with each. Note that most current core sets focus on benefit, and the 
Framework does not require core set developers to include separate benefit and harm 
domains. For Manifestations, we stress that symptoms and signs of the health condition per 
se belong here, as target of benefit; their impact (if deemed core) should be separately 
measured and placed under life impact. For example, in polymyalgia rheumatica 
manifestations included only systemic inflammation (15), but in psoriatic arthritis it also 
included separate domains for musculoskeletal and skin disease activity.(16) For Life Impact 
both included the core domains of pain and physical function, to which polymyalgia added 
stiffness, and psoriatic arthritis patient global assessment, fatigue, and health-related quality 
of life. Adverse event reporting is mandatory in trials, and the requirements for reporting are 
best seen as separate from the development of a core set. Nevertheless, all such events can 
be conceptually placed in core areas, and where necessary, specific core domains of harm 
can be specified. For example, developers could decide to include  ‘ŝŶĨĞĐƚŝŽŶ ? as a core 
domain.  
For Impact, historically effort has been targeted at defining the core domains necessary to 
document benefit. For harm, it quickly became clear that adverse events were not 
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adequately integrated into the model.  At OMERACT 2018, pivotal discussions between 
stakeholders were held at a pre-conference meeting (17). One key finding spurred the 
current elaboration of the framework: patients explained that they usually did not 
experience adverse effects or harm from treatment as a series of discrete events that could 
be captured according to regulatory guidelines (18). Instead, they described harm as an 
ŝŶƚĞƌŵŝƚƚĞŶƚŽƌĐŽŶƚŝŶƵŽƵƐĚŝƐĐŽŵĨŽƌƚ ‘ŝŶƚŚĞďĂĐŬŐƌŽƵŶĚ ? ?ŽĨƚĞŶŶŽt serious enough to 
warrant priority in a consultation with their physician, but nevertheless significantly 
impacting well-being and participation as well as potentially choice of therapy.(17) For 
ĞǆĂŵƉůĞ ?ĂƉĂƚŝĞŶƚĚĞƐĐƌŝďĞĚŚĞƌĚĂǇƐĨŽůůŽǁŝŶŐŵĞƚŚŽƚƌĞǆĂƚĞŝŶŐĞƐƚŝŽŶĂƐ ‘ĂĨĞĞůŝŶŐŽĨ
nausea, fatigue, being ŐĞŶĞƌĂůůǇƵŶǁĞůůƚŚĂƚŚŝŶĚĞƌƐƵŶĚĞƌƚĂŬŝŶŐĂĐƚŝǀŝƚŝĞƐ ? ?Currently this 
potential core domain of harm is not captured at all, or only indirectly through global patient 
ĂƐƐĞƐƐŵĞŶƚƐŽĨŚĞĂůƚŚ ?tĞŚĂǀĞŶŽǁĂĚĚĞĚŝƚƵŶĚĞƌƚŚĞůĂďĞů ‘ƵŶŝŶƚĞŶĚĞĚŝŵƉĂĐƚŽĨ
ƚƌĞĂƚŵĞŶƚŽŶĨƵŶĐƚŝŽŶŝŶŐ ?ƉĂƌƚŝĐŝƉĂƚŝŽŶ ? ?tĞĞǆƉĞĐƚƚŚŝƐĚŽŵĂŝŶƚŽďĞĐŽŵĞĐŽƌĞŝŶŵĂŶǇ
future core sets. It has already been picked up in psoriatic arƚŚƌŝƚŝƐĂƐ ‘ƚƌĞĂƚŵĞŶƚďƵƌĚĞŶ ?
ĂŶĚƉůĂĐĞĚŝŶƚŚĞ ‘ƌĞƐĞĂƌĐŚĂŐĞŶĚĂ ?ƌŝŶŐŽĨƚŚĞKDZdŽŶŝŽŶ ? ? ?6,19) In addition, and 
ĞƐƉĞĐŝĂůůǇƉĞƌƚŝŶĞŶƚĨŽƌƉĂƚŝĞŶƚƐǁŝƚŚĂĐŚƌŽŶŝĐĐŽŶĚŝƚŝŽŶ ?ƚŚĞĐŽŶĐĞƉƚ ‘ďƵƌĚĞŶŽĨƚƌĞĂƚŵĞŶƚ ?
ŚĂƐďĞĞŶŝŶƚƌŽĚƵĐĞĚƚŽĚĞƐĐƌŝďĞĂƉĂƚŝĞŶƚ ?Ɛ ‘ǁŽƌŬůŽĂĚ ?ŝŶƚĞƌŵƐŽĨƚŝŵĞĂŶĚĞĨĨŽƌƚƚŽĂĚŚĞƌĞ
to treatment regimens (including taking drugs), visiting health professionals, and other 
health-related activities.(20,21) We now add the burden on personal finances that can also 
constitute real life impacts for patients, including their ability to continue a course of 
treatment.  
Regarding the area of Death/Lifespan, OMERACT acknowledges that for many health 
conditions, death is very rare in clinical trials. However, OMERACT Core Outcome Sets should 
follow clinical trial reporting guidelines that mandate reporting the number of deaths as 
 15 
adverse event. OƵƌĐƵƌƌĞŶƚƚŚŝŶŬŝŶŐŝƐƐŚŽǁŶďǇƚŚĞĚŝƐƚŝŶĐƚŝŽŶďĞƚǁĞĞŶ ‘^ƵƌǀŝǀĂů ?ĂƐ a 
domain to show benefit of interventions for conditions that are potentially fatal, and 
 ‘DŽƌƚĂůŝƚǇ ?ĨŽƌƚŚĞŽƚŚĞƌĐŽŶĚŝƚŝŽŶƐ ?ǁŚĞƌĞĚĞĂƚŚŝƐlikely only relevant as an adverse event 
in the clinical trial setting. The term lifespan was chosen to describe the duration of living 
rather than focusing on the discrete event of death. 
For Societal Impact, the domain of costs is placed in between benefit and harm. 
dƌĂĚŝƚŝŽŶĂůůǇ ?ĐŽƐƚƐĂƌĞƐĞĞŶĂƐ ‘ŚĂƌŵ ?ƚŽďĞƚƌĂĚĞĚĂŐĂŝŶƐƚƚŚĞďĞŶĞĨŝƚƐŽĨƚŚĞŝŶƚĞƌǀĞŶƚŝŽŶ ?
However, cost could also be the target of an intervention, and decreases seen as benefit. 
Domain selection process 
The process to select domains is described in the OMERACT Handbook (19),and updated in 
the OMERACT 2018 conference proceedings (22). Briefly, core set developers must name at 
least one domain in each of the areas: Manifestations, Life Impact, and Death/Lifespan. 
Guidance has been developed for placement of domains in an area. If properly supported by 
arguments and agreed to by the OMERACT community, domains can be shared between 
areas (as described above) and choices for domains can be made on the benefit and on the 
harm side (as in the case of Mortality for non-fatal conditions). 
Setting; Personal and Environmental Context 
/ŶƚŚĞŽƌŝŐŝŶĂůĨƌĂŵĞǁŽƌŬƉĂƉĞƌǁĞƐƚĂƚĞĚ P ‘Core set developers need to specify the setting 
of the core set, and consider if any contextual factors need to be documented in every trial ?. 
Setting (or scope) includes the health condition, target population for the intervention, type 
of intervention, and so on. Contextual factors can be defined as those that are not the 
primary object of research but that may influence the results or the interpretation of the 
results. These include potential confounders and effect modifiers (most of which should be 
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eliminated by randomization), as well as factors that define the generalizability of the study 
findings. ?(1) In the current elaboration, the label has been made more specific by following 
the ICF terminology and ĂĚĚŝŶŐ ‘ƉĞƌƐŽŶĂůĂŶĚĞŶǀŝƌŽŶŵĞŶƚĂů ?, but otherwise things are 
unchanged. An OMERACT special interest group is exploring the process of selecting 
important and core contextual factors for a core set (23). Discussions are ongoing, but we 
posit that consideration of context is important in at least three phases: 1) domain selection;  
2) instrument selection (for correct interpretation of measurements); and 3) consideration 
of other factors that should be included as effect modifiers/confounders in the analysis and 
interpretation of the trial.   
Box 1 outlines the changes incorporated into the revised Framework as described above.  
[INSERT Box 1] 
 
Conclusion 
The OMERACT Filter 2.0 framework and process has been widely quoted and implemented 
both within- and outside OMERACT. We hope the current elaboration, termed  ‘OMERACT 
&ŝůƚĞƌ ? ? ? ?clarifies and helps to solve problems encountered by users. 
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Figure Legends 
Figure 1.   The OMERACT Filter 2.0 Framework as published in 2014 (1).   
Figure 2.   Updated OMERACT Filter 2.1 Framework. All measurable aspects of health 
conditions (diseases) are captured in the core areas. These contain all the domains in which 
effects of an intervention can be measured. Most core set developers focus on identifying 
core domains for intended benefits, i.e. improvements on disease-related manifestations 
and impacts. But conceptually the areas can also be used to define core harm domains 
where required, i.e. the unintended effects, e.g. worsening of comorbidity and negative 
impacts. Core domain sets are defined for a specific context, and should contain at least one 
domain from each of the core areas (societal/resource use is optional).  
 
Figure 3.  Example domains within the updated OMERACT Filter 2.1 Framework. Mandatory 
adverse event reporting is not within the scope of a core domain set, except for the area of 
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Death/Lifespan in settings where death is a rare event. Societal and resources use are 
outside of the shaded boxes as the same indicator such as cost can represent both intended 
effects and harms.    
